Endoplasmic reticulum stress and expression of nitric oxide synthases in heart failure with preserved and with reduced ejection fraction — pilot study
, 1, 1, 1, 1, 2, 1
Abstract
Background: Unfolded Protein Response (UPR), endoplasmic reticulum (ER) stress, and inducible nitric oxide synthase (iNOS) overexpression have been found to influence heart failure with preserved ejection fraction (HFpEF) pathogenesis. Their importance in heart failure with reduced ejection fraction (HFrEF) is not entirely established; there is little data involving a detailed comparison between HFpEF and HFrEF from this perspective. This pilot study aimed to compare circulating levels of Glucose-regulated protein 78kDa (GRP78) (ER — stress marker) and all NOS isoforms between both HFpEF and HFrEF and to analyze the correlation between these markers and the clinical characteristics of the patients.
Methods: Forty-two patients with HFpEF and thirty-eight with HFrEF were involved in this study. Clinical characteristics and echocardiographic data were obtained. Basic laboratory tests were performed and ELISA tests for iNOS, endothelial NOS (eNOS), neuronal NOS (nNOS), and GRP78.
Results: Patients with HFpEF had lower circulating levels of GRP78 and higher iNOS concentrations when compared to HFrEF patients (P = 0.023, P < 0.0001, accordingly). The subgroup of the HFpEF population with eGFR < 60 mL/min/1.73m2 had higher nNOS and eNOS levels than HFpEF patients with normal GFR (P = 0.049, P = 0.035, respectively). In the HFrEF subgroup, patients with coexistent diabetes mellitus had elevated concentrations of nNOS compared to the subpopulation without diabetes mellitus (P = 0.041). There was a positive correlation between eNOS and nNOS concentrations (ρ = 0.86, P < 0.0001).
Conclusions: In HFpEF, there is a more intensified iNOS overexpression, while in HFrEF, ER stress is more prominent.
Keywords: nitrosative stressoxidative stressendoplasmic reticulum stressheart failure with preserved ejection fractionheart failure with reduced ejection fraction
References
- Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J . 2021; 42(48): 4901.
- Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023; 118(17): 3272–3287.
- Simmonds SJ, Cuijpers I, Heymans S, et al. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells. 2020; 9(1).
- Boulet J, Sridhar VS, Bouabdallaoui N, et al. Inflammation in heart failure: pathophysiology and therapeutic strategies. Inflamm Res. 2024; 73(5): 709–723.
- Alcaide P, Kallikourdis M, Emig R, et al. Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction. Circ Res. 2024; 134(12): 1752–1766.
- Simmonds SJ, Cuijpers I, Heymans S, et al. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells. 2020; 9(1).
- Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev. 2014; 19(5): 681–694.
- Schiattarella GG, Altamirano F, Tong D, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019; 568(7752): 351–356.
- Sabirli R, Koseler A, Mansur N, et al. Predictive Value of Endoplasmic Reticulum Stress Markers in Low Ejection Fractional Heart Failure. In Vivo. 2019; 33(5): 1581–1592.
- Minamino T, Komuro I, Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res. 2010; 107(9): 1071–1082.
- Vitadello M, Penzo D, Petronilli V, et al. Overexpression of the stress protein Grp94 reduces cardiomyocyte necrosis due to calcium overload and simulated ischemia. FASEB J. 2003; 17(8): 923–925.
- Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001; 357(Pt 3): 593–615.
- Zhang YH, Jin CZi, Jang JiH, et al. Molecular mechanisms of neuronal nitric oxide synthase in cardiac function and pathophysiology. J Physiol. 2014; 592(15): 3189–3200.
- Tran N, Garcia T, Aniqa M, et al. Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States. Am J Biomed Sci Res. 2022; 15(2): 153–177.
- Kourosh-Arami M, Hosseini N, Mohsenzadegan M, et al. Neurophysiologic implications of neuronal nitric oxide synthase. Rev Neurosci. 2020; 31(6): 617–636.
- Shah AM. Inducible nitric oxide synthase and cardiovascular disease. Cardiovasc Res. 2000; 45(1): 148–155.
- Aljada A, Dandona P. Nitric oxide synthase. Methods Mol Biol. 1998; 108: 191–198.
- Pérez-Torres I, Manzano-Pech L, Rubio-Ruíz ME, et al. Nitrosative Stress and Its Association with Cardiometabolic Disorders. Molecules. 2020; 25(11).
- Aliev G, Bodin P, Burnstock G. Free radical generators cause changes in endothelial and inducible nitric oxide synthases and endothelin-1 immunoreactivity in endothelial cells from hyperlipidemic rabbits. Mol Genet Metab. 1998; 63(3): 191–197.
- Al-Khlaiwi T, Habib SS, Al-Khliwi H, et al. Relationship of serum inducible and endothelial nitric oxide synthase with exercise in healthy adult males and patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2023; 27(10): 4619–4625.
- Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. Mol Med. 2000; 6(5): 347–373.
- Yasukawa T, Tokunaga E, Ota H, et al. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem. 2005; 280(9): 7511–7518.
- Guo Y, Wen J, He An, et al. iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation. J Adv Res. 2023; 43: 175–186.
- Zhao X, Zhang DQ, Song R, et al. The clinical significance of circulating glucose-regulated protein 78, Caspase-3, and C/EBP homologous protein levels in patients with heart failure. Heliyon. 2023; 9(2): e13436.
- Ma N, Xu N, Yin D, et al. Levels of circulating GRP78 and CHOP in endoplasmic reticulum stress pathways in Chinese type 2 diabetic kidney disease patients. Medicine (Baltimore). 2021; 100(33): e26879.
- Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007; 581(19): 3641–3651.
- Dickhout JG, Carlisle RE, Austin RC. Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res. 2011; 108(5): 629–642.
- Ren J, Bi Y, Sowers JR, et al. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat Rev Cardiol. 2021; 18(7): 499–521.
- Suyama K, Watanabe M, Sakabe K, et al. Overexpression of GRP78 protects glial cells from endoplasmic reticulum stress. Neurosci Lett. 2011; 504(3): 271–276.
- Damy T, Ratajczak P, Shah AM, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet. 2004; 363(9418): 1365–1367.
- Wu QQ, Xiao Y, Duan MX, et al. Aucubin protects against pressure overload-induced cardiac remodelling via the β -adrenoceptor-neuronal NOS cascades. Br J Pharmacol. 2018; 175(9): 1548–1566.
- Kolijn D, Pabel S, Tian Y, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc Res. 2021; 117(2): 495–507.
- Balakumar P, Chakkarwar VA, Krishan P, et al. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed Pharmacother. 2009; 63(3): 171–179.
- Tona F, Montisci R, Iop L, et al. Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2021; 22(1): 97–104.
- Fahey JM, Girotti AW. Nitric oxide-mediated resistance to photodynamic therapy in a human breast tumor xenograft model: Improved outcome with NOS2 inhibitors. Nitric Oxide. 2017; 62: 52–61.
- Chatterjee PK, Patel NSA, Sivarajah A, et al. GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003; 63(3): 853–865.
- Alderton WK, Angell ADR, Craig C, et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 2005; 145(3): 301–312.
- Wang X, Fang C, Liu X, et al. High Serum Levels of iNOS and MIP-1α are Associated with Post-Stroke Depression. Neuropsychiatr Dis Treat. 2021; 17: 2481–2487.
